Stock Groups

Roche family shareholders will maintain stability

© Reuters. FILEPHOTO: The logo of Roche Pharmaceutical Company in Rotkreuz, Switzerland. April 12, 2012. REUTERS/Michael Buholzer/File Photo

ZURICH (Reuters). Roche’s chief shareholder is confident that stability will be preserved at the company once the next generation of heirs joins the family group of investors. He spoke to NZZ am Sonntag.

“The new generation has the same values ​​as the older family members,” Andre Hoffmann, the great grandson of the company’s founder, told the newspaper in an article published on Sunday.

“Our role as the owner family is to enable Roche to focus on creating sustainable values ​​over the long term. The 63-year old spoke out for the family that owns 45.01%.

The pooling agreement among the descendants Fritz Hoffmann-La Roche’s founder was established in 1948. This agreement was then extended indefinitely in 2009. In 2019, a fifth generation joined the pool.

Hoffmann is also vice-chairman of Roche. He said that family ownership in large corporations does not always work.

It is great for the company if it works. He said that if it doesn’t work, it could be dangerous.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.